NUMERO: #20220286

Título: CHRONIC HYPERPLASTIC CANDIDIASIS AS A RARE ADVERSE EVENT OF SECUKINUMAB THERAPY

Nome do Apresentador: Maria Emília Mota Galdino FERREIRA

Categoria do Trabalho: Apresentação Oral de Pôster de (Série de) Casos Clínicos (PCC)

Área Temática: Estomatologia

Resumo: Secukinumab is an anti-IL-17A monoclonal antibody used for the treatment of psoriasis, a frequent chronic inflammatory skin disease. However, IL-17 is essential in immunity against oral opportunistic fungal pathogens therefore oral candidiasis can occur in patients treated with this drug, although oral adverse events of this therapy are not widely described. A 72-year-old male patient with arthritis psoriasis managed with Secukinumab 300 mg once a month, for 90 days, presented a burning white plaque on the mid dorsal posterior tongue. Fungal culture was performed and a diagnosis of oral candidiasis was established. Systemic and topical antifungal medication led to regression of the lesion and burning sensation resolution. No symptoms or recurrence of the lesion were observed after 6 months of follow up. This case highlighted the importance of monitoring patients who are under therapy with IL-17 blockers due to the risk of opportunistic infections.

Autor 1:  Maria Emília Mota Galdino FERREIRA

E-mail 1:  [email protected]

Autor 2:   Claudia Rebecca Costa Cavalcante SILVA

E-mail 2:  [email protected]

Autor 3 :  Letícia Beatriz da Cruz SANTOS

E-mail 3:  [email protected]

Autor 4:  Graziella Chagas JAGUAR

E-mail 4:  [email protected]

Autor 5:  Fábio de Abreu ALVES

E-mail 5:  [email protected]